US 11,752,134 B2
Composition for enhancing cognitive function, composition for remedying anxiety symptoms, and composition for suppressing cerebral atrophy
Hideaki Sato, Kawasaki (JP); Masako Yasui, Kawasaki (JP); Yusuke Adachi, Kawasaki (JP); Katsuya Suzuki, Kawasaki (JP); and Michihiro Takada, Kawasaki (JP)
Assigned to AJINOMOTO CO., INC., Tokyo (JP)
Filed by AJINOMOTO CO., INC., Tokyo (JP)
Filed on Aug. 25, 2020, as Appl. No. 17/1,776.
Application 17/001,776 is a continuation of application No. PCT/JP2019/008715, filed on Mar. 5, 2019.
Claims priority of application No. 2018-038950 (JP), filed on Mar. 5, 2018.
Prior Publication US 2020/0383952 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4172 (2006.01); A61P 25/28 (2006.01); A61K 31/198 (2006.01); A61K 31/405 (2006.01)
CPC A61K 31/4172 (2013.01) [A61K 31/198 (2013.01); A61K 31/405 (2013.01); A61P 25/28 (2018.01)] 5 Claims
 
1. A method for improving cognitive function, comprising administering to a subject in need thereof a composition comprising the following amino acids at the following contents relative to the total content of leucine, lysine, valine, isoleucine, phenylalanine, histidine, and tryptophan:
leucine 25 mol % to 45 mol %,
phenylalanine 20 mol % to 40 mol %,
lysine 10 mol % to 30 mol %,
valine 2 mol % to 7 mol %,
isoleucine 5 mol % to 15 mol %,
histidine 2 mol % to 10 mol %, and
tryptophan 0.1 mol % to 2 mol %.